BioSpace News Archive

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 346 owned and/or operated outpatient imaging centers, reported financial results for its first quarter of 2021.

Initiated darovasertib plus crizotinib combination Phase 1/2 dose expansion based on early clinical activity observed in first cohort; additional dose exploration ongoing

Bionomics Limited, a global, clinical stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety efficacy signals in Generalised Anxiety Disorder patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder in the middle of this year.

DaVita Kidney Care announced the expansion of its home kidney care program to include the HomeChoice Claria Automated Peritoneal Dialysis system enabled by Sharesource remote patient monitoring from Baxter International Inc., a global innovator in renal care.

Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou.

Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from second cohort anticipated Q3 2021

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD)

So-Young International Inc., the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, announced that it will report its financial results for the first quarter ended March 31, 2021, before U.S. markets open on May 19, 2021.

ALX Oncology Holdings Inc. in partnership with Merck, known as MSD outside the United States and Canada, announced the first patient has been dosed in the Phase 2 ASPEN-03 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA®, Merck’s anti-PD-1 therapy, for the treatment of patients with advanced head and neck squamous cell carcinoma.